At the time of writing, Catalyst Pharmaceuticals Inc [CPRX] stock is trading at $24.19, up 0.04%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CPRX shares have gain 7.27% over the last week, with a monthly amount glided 4.36%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Catalyst Pharmaceuticals Inc [NASDAQ: CPRX] stock has seen the most recent analyst activity on February 04, 2025, when Robert W. Baird initiated its Outperform rating and assigned the stock a price target of $28. Previously, Stephens started tracking the stock with Overweight rating on November 18, 2024, and set its price target to $35. On March 14, 2024, Citigroup initiated with a Buy rating and assigned a price target of $27 on the stock. BofA Securities started tracking the stock assigning a Buy rating and suggested a price target of $23 on March 07, 2024. Oppenheimer initiated its recommendation with an Outperform and recommended $30 as its price target on December 21, 2023. ROTH Capital downgraded its rating to Neutral for this stock on August 24, 2022, and upped its price target to $15.50. In a note dated September 21, 2018, Cantor Fitzgerald initiated an Overweight rating.
For the past year, the stock price of Catalyst Pharmaceuticals Inc fluctuated between $19.05 and $26.58. Currently, Wall Street analysts expect the stock to reach $33 within the next 12 months. Catalyst Pharmaceuticals Inc [NASDAQ: CPRX] shares were valued at $24.19 at the most recent close of the market. An investor can expect a potential return of 36.42% based on the average CPRX price forecast.
Analyzing the CPRX fundamentals
According to Catalyst Pharmaceuticals Inc [NASDAQ:CPRX], the company’s sales were 578.20M for trailing twelve months, which represents an 15.31% jump. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at 0.45%, Pretax Profit Margin comes in at 0.49%, and Net Profit Margin reading is 0.38%. To continue investigating profitability, this company’s Return on Assets is posted at 0.21, Equity is 0.26 and Total Capital is 0.28. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.97 points at the first support level, and at 23.75 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.45, and for the 2nd resistance point, it is at 24.72.
Ratios To Look Out For
It is important to note that Catalyst Pharmaceuticals Inc [NASDAQ:CPRX] has a current ratio of 6.62. In addition, the Quick Ratio stands at 6.40 and the Cash Ratio stands at 5.36. Considering the valuation of this stock, the price to sales ratio is 5.14, the price to book ratio is 3.24 and price to earnings (TTM) ratio is 14.12.
Transactions by insiders
Recent insider trading involved Harper Molly, Director, that happened on Dec 12 ’25 when 26746.0 shares were sold. Director, Harper Molly completed a deal on Dec 12 ’25 to buy 26746.0 shares. Meanwhile, Chief Commercial Officer Del Carmen Jeffrey sold 10983.0 shares on Nov 26 ’25.
